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THERE IS CURRENTLY NO CLINICAL TOOL for the routine measurement of total-body skeletal muscle mass. Such a method would permit diagnosis of skeletal muscle wasting conditions, enable monitoring of rates of skeletal muscle mass change in disease and therapy, and provide a research tool for the routine measurement of muscle mass in health and disease.
While considerable advances have been made in measuring skeletal muscle size by computerized axial tomography (CT) (23) or magnetic resonance imaging (MRI) (14, 22) , these approaches have significant limitations. These methods do not directly measure muscle amount and are subject to error when body water volume changes due to dehydration or disease. Imaging methodologies are also time consuming, costly, and labor intensive, and in the case of CT have the added disadvantage of radiation exposure. Neutron activation analyses of total body nitrogen or total body protein has been indirectly related to skeletal muscle mass (20) . Dual energy X-ray absorptiometry (DEXA) has emerged as a potential precise measure of lean mass; however, it also serves as only an indirect measurement of total-body skeletal muscle mass (14) and its clinical use for determination of changes in muscle mass may be very limited due to instrumentation availability, particularly in field studies, and cost.
The most direct current approach is 24-h urinary creatinine excretion. This method is based on several well-established aspects of creatine and creatinine biology (12) . An estimated 98% of total-body creatine is found in skeletal muscle (13) . Creatine synthesis occurs in the liver and kidney (muscle has no creatine synthesis capacity) and is accumulated in muscle against a concentration gradient via specific active transport from plasma (27) . Creatine content of skeletal muscle is relatively constant (4) . Creatine is metabolized to its nonionic cyclic derivative creatinine at a constant rate (ϳ1.7% per day) (11) by a nonenzymatic hydrolytic cyclization that is irreversible in vivo (5) , and creatinine rapidly diffuses from muscle into plasma and urine with no reuptake into muscle (27) . Creatinine is not significantly otherwise metabolized, and creatinine excretion under steady-state conditions therefore equals creatinine production and is proportional to the total-body creatine pool size and skeletal muscle mass (12, 27) . A recent analysis of 24-h urinary creatinine level compared with CT estimate (24) demonstrated that 1 g of urinary creatinine excreted per day equals 21.8 kg of wet weight skeletal muscle in healthy men. This technique is not practical as a clinical tool, however, due to requirement for complete collection of all urine in a 24-h period (12) . Any errors in timing or completeness of bladder emptying, etc., are introduced into estimates of total creatinine excretion rate by this approach. Thus a method for estimating whole body creatine stores without requiring timed collections of urine would potentially be very attractive. There have been previous estimates made of total body creatine pool size using isotope labeled creatine, and measuring isotope enrichment in skeletal muscle biopsies to determine creatine pool size in rats (17) and humans (15) .
We hypothesized that urinary enrichment of D 3 -creatinine at isotopic steady state after a single defined tracer dose of D 3 -creatine could be used to calculate total body creatine pool size and, thus, skeletal muscle mass. We report here the development of the D 3 -creatine method for determination of total body creatine pool size and its application in crosssectional studies of muscle accrual in growing rats or muscle atrophy induced by the corticosteroid, dexamethasone. We also compare creatine pool size to lean body mass determined by DEXA or quantitative magnetic resonance (QMR) to provide preclinical validation and explore the potential utility and limitations of this new method.
MATERIALS AND METHODS

Method development overview.
Testing of the study hypothesis and validation of the method in rats required a number of steps: first, the bioavailability of oral creatine needed to be established; second, determination of an appropriate dose of D 3-creatine that would result in measurable enrichment levels of labeled creatinine in urine without loss (spillage) of D3-creatine prior to its transport into skeletal muscle (because the precise dose of label administered into a pool must be known for use of an isotope dilution method); third, determination of intramyocellular enrichment and distribution of D 3-creatine; fourth, determination of the time to reach isotopic steady state for enrichment of urinary D3-creatinine; fifth, determination that urinary D3-creatinine enrichment reflected intramyocellular enrichment of D3-creatine; and sixth, comparison of the determination of total body creatine with fat-free mass determined by an independent method. Finally, validation of the method was established by application in rats of different ages that are adding muscle mass through growth and rats treated with dexamethasone to decrease muscle mass. D 3-creatine source. D3-creatine was purchased from Sigma-Aldrich, St. Louis, MO [material number 616249, Creatine-D3 H2O (methyl-D3), 98%], was dissolved in pure H2O immediately before dosing.
Rats. Male Crl:CD (SD) rats (Charles River) were used. Rats were acclimatized for 1 wk before study initiation. All studies were conducted after review and approval by the GlaxoSmithKline Institutional Animal Care and Use Committee and in accordance with the GlaxoSmithKline Policy on the Care, Welfare and Treatment of Laboratory Animals.
Assessment of D 3-creatine concentration in urine and plasma. Rat urine samples were stored at Ϫ80°C until analyzed for D3-creatine. The samples were thawed at room temperature and centrifuged for 20 min at 2,055 g at 10°C. Twenty-five-microliter aliquots were prepared by protein precipitation with 175 l acetonitrile:methanol (1:1). The samples were vortexed for 5 min and centrifuged for 20 min at 2,304 g at 10°C. Then 50 l of supernatant was transferred to clean 96-well plates containing 150 l acetonitroile per well and vortexed at 1,000 rpm for 30 s.
Rat plasma samples were stored at Ϫ80°C until analyzed for D 3-creatine. The samples were thawed at room temperature, and 40-l aliquots were prepared by protein precipitation with 200 l methanol. The samples were vortexed for 5 min and centrifuged for 20 min at 2,055 g at 10°C. Then 150 l of supernatant was transferred to clean 96-well plates and evaporated to dryness with nitrogen at 50°C. The samples were reconstituted with 150 l methanol and vortexed at 1,500 rpm for 1 min.
The urine and plasma samples were analyzed by ultra-high-performance liquid chromatography/mass spectrometry/mass spectrometry using positive-mode turbo-ion spray. The D 3-creatine was monitored using the multiple reaction monitoring m/z transition of 135 ¡ 47. The calibration curve for D3-creatine in rat urine ranged from 2.5 to 2,500 ng/ml using 1/x weighting for the linear regression analysis. Quality control urine samples, obtained from a separate weighing, were prepared in pooled control rat urine at 7.5, 15, 150, 750, and 1,500 ng/ml. The calibration curve for D 3-creatine in rat plasma ranged from 0.5 to 2,500 ng/ml using 1/x 2 weighting for the linear regression analysis. Quality control plasma samples, obtained from a separate weighing, were prepared in pooled control rat plasma at 7.5, 75, 750, and 1,500 ng/ml. D 3-creatine pharmacokinetic analyses. A single intravenous (0.5 mg/kg) bolus dose of D 3-creatine in 0.9% saline was administered to nonfasted male CD rats (n ϭ 5) through a femoral cannula at a dose volume of 1 ml/kg. A single oral (0.5 mg/kg) dose of D 3-creatine in 0.9% saline was administered to nonfasted male CD rats (n ϭ 5) via gavage at a dose volume of 2 ml/kg. Serial blood samples (0.25 ml) were collected from each animal via the jugular vein cannula at 0.083 (iv only), 0.25, 0.5, 1, 1.5 (oral only), 2, 4, 6, 8, 24 , and 32 h postdose and treated with EDTA (anticoagulant). The blood samples were centrifuged to obtain plasma, and the resulting plasma samples were stored frozen at Ϫ80°C until analyzed.
The primary purpose of this pharmacokinetic study was to estimate the oral bioavailability of D 3-creatine in plasma following a single, low oral and intravenous dose. Therefore a noncompartmental analysis was chosen to analyze individual animal concentration-time data using the linear/log trapezoidal method in Phoenix WinNonlin 6.1 (Pharsight, St. Louis, MO) to determine the terminal elimination half-life (t 1/2) and area under the plasma concentration-time curve extrapolated to infinity (AUC0-inf). Following intravenous dosing the clearance (CL) and volume of distribution at steady state (Vss) were also determined. After oral dosing the maximum plasma concentration observed (Cmax) and time of maximum plasma concentration (Tmax) were observed values. Oral bioavailability (F) was determined by dividing the dose-normalized oral AUC0-inf for each orally dosed animal by the mean dose-normalized intravenous AUC0-inf and multiplying by 100.
D3-creatine dilution protocol. The day prior to study, rat body weight and lean body mass (LBM) were determined. LBM was determined in conscious rats using QMR on an EchoMRI-700 (Echo Medical Systems, Houston, TX), or in isoflurane-anesthetized rats by DEXA using a Hologic 4500 Elite densitometer (Hologic, Bedford, MA). The day of study, rats were given an oral dose of D3-creatine at 10 AM. The same dose was used for all rats for consistency and precision in dosing, and the dose in all studies was 0.55 mg of the D3-creatine monohydrate per rat (based on a dosage of 1 mg/kg in our 17-wk-old rat group with a mean body weight of 550 g), corresponding to 0.475 mg actual D3-creatine per rat. Rats were immediately placed in single house metabolic cages, with ad libitum normal chow and water, for collection of urine over the next 72 h. Urine samples were collected at 10 AM to 4 PM and 4 PM to 10 AM intervals, clarified by centrifugation, and stored at Ϫ80°C. During the 48-to 72-h urine collection, rat chow was removed and replaced with Diet Gel 76A (Clear H2O, Portland, ME), which is creatine free, to minimize the potential impact of any creatine or creatinine leaching from food into urine. (Contamination from food during urine collection proved to be negligible as we did not see a difference between 48-h and 72-h urinary creatinine enrichments when using creatine-free food only for the 72-h collection.) D3-creatine was quantified in all urine samples to determine the amount of tracer spillage in all urine as percent of the dose.
Enrichment of D3-creatine in muscle samples, and D3-creatinine in urine samples by gas chromatography-pyrolysis-isotope ratio mass spectrometry (IRMS).
Five-hundred microliters of urine was diluted 2:1 with 0.2% H3PO4 solution, centrifuged cold at 3,000 g for 10 min, then passed over a strata-x-c polymeric strong cation-exchange column (Phenomenex). Columns were washed with 0.1 N HCl solution, followed by methanol. Creatine and creatinine were coeluted with a solution of 7% NH4OH in methanol. Creatinine and creatine were converted to the tert-butyldimethylsilyl derivative with 70 l of CH3CN:MTBSTFA (Sigma-Aldrich, St. Louis, MO) (2:1 by volume) at 60°C for 40 min (adapted from Ref. 8 ).
2 H isotopic enrichments of D3-creatinine samples were measured by IRMS using a Delta Plus XP isotope ratio mass spectrometer with GC-Isolink interface (Thermo Scientific, Bremen, Germany) and 7890N gas chromatograph (Agilent, Santa Clara, CA). Samples were injected onto an Rtx-50 column (30 m, 0.25 mm ID, 0.25-m film thickness, Restek, Bellefonte, PA) in splitless mode with injector at 300°C and constant 2 ml/min column flow. The GC oven program was 150°C for 2 min, 20°C/min to 190°C, hold 2 min, 10°C/min to 200°C, hold 0.5 min, 30°C/min to 310°C, hold 2.3 min (total 13.4 min). Enrichments were determined as mole percent excess (MPE) by comparison of the unknown samples to a standard curve generated with gravimetrically prepared working lab standards of known enrichments against an internal deuterium/hydrogen standard.
Skeletal muscle samples (250 mg) were homogenized in cold deionized water with 150 l of zirconia beads in a Fast prep tissue homogenizer (MP Biomedicals, Solon OH). When 250 mg of muscle was not available for the smaller muscles, the entire muscle was homogenized. Proteins were precipitated with cold acetonitrile (6:1). Supernatant was evaporated to dryness, resuspended in 2% H3PO4, and further prepared as described for urine.
Cross-sectional studies of muscle accrual or atrophy. Two crosssectional studies were done. The first study used two groups, 10 rats per group, aged 9 or 17 wk at the time of D 3-creatine administration, to examine creatine pool size as a simple example of muscle accrual (growing rats).
The second study used two groups (n ϭ 10) of 20-wk-old rats to examine creatine pool size after a 2-wk treatment with dexamethasone to induce skeletal muscle atrophy. The rats were blocked to have an equal distribution of LBM (by QMR) at the start of treatment. One group received daily subcutaneous injection for 2 wk with saline vehicle and the other group received dexamethasone (Sigma-Aldrich D2915 Dexamethasone-Water Soluble; 2 mg/kg for first week; 0.1 mg/kg for second week). These rats were thus 22 wk of age at time of D 3-creatine administration.
Skeletal muscle samples [soleus, tibialis anterior (TA), extensor digitorum longus (EDL), quadriceps (quads), gastrocnemius (gastroc)] were dissected and weighed at necropsy from the 20-to 22-wk-old rats in the muscle atrophy study. Muscle samples immediately snap-frozen in liquid nitrogen and stored at Ϫ80°C.
Statistics. The data were analyzed in SAS 9.2 (SAS Institute, Cary, NC) and figures were created in JMP 9.0.1 (SAS Institute, Cary, NC).
All results in this manuscript are provided as means Ϯ SD. The standard ANOVA approach was used to determine P values for group comparisons except when multiple observations were being collected from each rat (Figs. 1A and 5), where P values were derived by fitting a linear mixed model with fixed main and interaction effects for group factors and a random effect for rat with prespecified contrasts. Bonferroni correction was used to adjust for multiple comparisons.
Linear regression and Pearson's correlation coefficient were used to assess linear relationships and the strength of the relationships. Clustering of groups can lead to artificially large correlation coefficients, so to adjust for grouping effects, we also calculated correlation coefficients between age (and treatment) effect-adjusted residuals. Residuals are the observable estimates of the unobservable statistical error. They are calculated by subtracting the age (and/or treatment) group means, i.e., the predicted values, from the actual observed values. Note that it is expected that a residual value can sometimes be a negative number; this happens when the mean value for a specific age/treatment group is larger than the observed value for a rat from that group. In addition to calculating the correlation coefficient, the null hypothesis H o ("No linear relationship exists between lean body mass and total-body creatine pool size") was tested and the P values were provided. 3 -creatine dilution method. Pilot studies established that a dose of Յ1 mg D 3 -creatine/kg body weight in rats yielded enrichments of D 3 -creatine in muscle and urinary creatine that were sufficiently greater than the sensitivity limit of IRMS (data not shown). We then studied in more detail the pharmacokinetics of this tracer dose D 3 -creatine in rats. Intravenous administration of 0.5 mg/kg resulted in low clearance (9.6 Ϯ 1.1 ml·min Ϫ1 ·kg Ϫ1 ), a large volume of distribution (8.2 Ϯ 1.2 l/kg), and a long plasma half-life (21 Ϯ 8 h). Oral administration of 1 mg/kg resulted in rapid absorption with a time of maximum plasma concentrations of ϳ1.5 h, and comparing the dose-normalized AUC of oral and intravenous administration (1,791 Ϯ 259 and 1,748 Ϯ 207 h·ng·kg·ml Ϫ1 ·mg Ϫ1 , respectively), yielded 102 Ϯ 15% bioavailability.
RESULTS
Establishing a dose of D 3 -creatine suitable for use in the D
All subsequent studies to establish and validate the D 3 -creatine dilution method used a dose of 0.475 mg D 3 -creatine/ rat. Urinary spillage of D 3 -creatine following oral administration of this dose occurred mainly within the first 24 h, and total urinary spillage in the four groups of rats studied were as follows: 9-wk-old rats, 0.19 Ϯ 0.05% of total D 3 -creatine dose; 17-wk-old rats, 1.23 Ϯ 1.31%; 22-wk-old rats, 0.31 Ϯ 0.04%; 22-wk-old rats treated with dexamethasone, 0.22 Ϯ 0.04%.
These results indicated the oral dose of D 3 -creatine used in our subsequent experiments was rapidly and completely absorbed and reached the systemic circulation with minimal urinary spillage, suggesting that Ͼ99% of the D 3 -creatine tracer dose is available to equilibrate with the body creatine pool.
Determining urinary D 3 -creatine enrichment and the time to isotopic steady state. We used growing rats for the first study testing the ability of the creatine dilution method to distinguish different creatine pool sizes. In a cross-sectional study, a single oral dose of 0.475 mg D 3 -creatine per rat was given to two groups of rats, 9 and 17 wk of age, followed by urine collection over the next 0 -24, 24 -48, and 48 -72 h. As expected, the larger, older rats had significantly lower urinary D 3 -creatinine enrichment (expressed as mole percent excess, MPE) at all time points than the younger, smaller rats, reflecting greater dilution of the D 3 -creatine tracer in the total-body creatine pool. For both age groups, urinary enrichment was highest at 24 h and stable between 48 and 72 h, indicating isotopic steady state was achieved between 24 and 48 h after the tracer D 3 -creatine dose (Fig. 1A) . It is anticipated that due to spillage within the first few hours, urinary enrichment would be higher in that period, as we have seen, and may well have peaked earlier than 24 h. We have not determined the precise time between that peak enrichment (up to 24 h) and when enrichment stabilizes (isotopic steady state) by 48 h. We anticipate that after isotopic steady state is reached, the loss of enrichment should mirror loss of the conversion of the muscle creatine pool to creatinine, which is ϳ2% per day (21, 27) , too small a rate in the present study to recognize as significant between 48 and 72 h in these groups of 10 rats.
Total-body creatine pool size and correlation to lean body mass in skeletal muscle accrual (growing rats). We calculated total body creatine pool size using the classic formula for determination of pool size based on enrichment of a tracer, assuming a single creatine pool (26) : the D 3 -creatine dose (0.475 mg) divided by the D 3 -creatinine enrichment (MPE/ 100). Figure 1B shows the total body creatine pool sizes calculated from urinary enrichment 72 h after the tracer dose for the 9-and 17-wk-old rat groups and indicates the creatine pool size for the larger, older rats is significantly larger than for the smaller, younger rats.
The day before giving the tracer dose of D 3 -creatine, LBM in all rats was assessed by either QMR or DEXA. LBM by QMR and creatine pool size are significantly correlated, even after adjusting for age effect (Fig. 2) . LBM by QMR and creatine pool size are also significantly correlated within each age group (Fig. 3) . LBM by DEXA and creatine pool size are significantly correlated within the 17-wk-old age group (r ϭ 0.7123, P ϭ 0.0208).
Total body creatine pool size and correlation to LBM mass in skeletal muscle wasting (dexamethasone-induced atrophy). In a second cross-sectional study, we used an older rat age group, still within the rat growth phase (22 wk of age), and this time treated once daily subcutaneously for the previous 2 wk with either saline vehicle, or dexamethasone to induce skeletal muscle atrophy.
As with the first cross-sectional study with 9-and 17-wk-old rats, isotopic steady state was reached between 48 and 72 h (data not shown). Fig. 1 . Urinary D3-creatinine enrichment and total body creatine pool size in growing rats. A: urinary D3-creatinine enrichment (expressed as mole percent excess, determined by isotope ratio mass spectrometry) in 9-wk-old (mean body weight 304 Ϯ 11 g, n ϭ 10) and 17-wk-old (mean body weight 553 Ϯ 39 g, n ϭ 10) rats at the indicated time after a single oral 0.475-mg dose of D3-creatine, showing achievement of isotopic steady state by 48 h, and clear separation of growing rat age groups (Bonferroni adjusted P Ͻ 0.001 between groups at all times; within groups, the difference between 48 and 72 h is not significant). B: creatine pool size calculated from 72-h urinary D3-creatinine enrichments for the rat groups in figure, showing clear separation of age groups (P Ͻ 0.0001). Fig. 2 . Correlation between lean body mass (LBM) by quantitative magnetic resonance (QMR) and total body creatine pool size, adjusted for age effect, for the rat groups in Fig. 1 (r ϭ 0.6898, P ϭ 0.0008). Compared with vehicle-treated controls, dexamethasone induced a significant reduction in LBM (353 Ϯ 32 vs. 459 Ϯ 45 g, P Ͻ 0.001) and a significant reduction in total body creatine pool size (1,255 Ϯ 130 vs. 1,853 Ϯ 228 mg, P Ͻ 0.001). As in the growing rat study, LBM and creatine pool size were significantly correlated, even after taking into account treatment effect in the statistical evaluation (Fig. 4) .
Comparison of urinary and skeletal muscle enrichment. Individual skeletal muscles from the 22-wk-old rat study were dissected and examined for differences in D 3 -creatine enrichment, and compared with urinary D 3 -creatinine enrichment. Across skeletal muscle types, the oxidative type 1 fiber-rich soleus had significantly higher enrichment than all other muscles or urine (Fig. 5) . This observation is consistent with the findings of Brault and Terjung (7), who found that soleus had both lower total creatine concentrations and higher rates of creatine uptake compared with more glycolytic muscle types. Urinary enrichment was more in line with the enrichment in skeletal muscles of predominantly glycolytic fiber composition, trending to be slightly lower than muscle, and significantly lower only compared with the TA muscle in the vehicletreated group (Fig. 5) .
Interrun variability in urinary enrichment determinations and comparisons across the two cross-sectional studies. Duplicate urine aliquots from 10 urine samples from the vehicletreated group in the 22-wk-old rat study were processed and analyzed on separate days to assess interrun variability in the IRMS D 3 -creatinine enrichment determinations. The two runs yielded values of 0.025 Ϯ 0.004 and 0.024 Ϯ 0.003 MPE. Further statistical evaluation indicated that the estimated standard deviation of a response from a randomly chosen rat on a random day is 0.0035% (CV ϭ 14.3), and that 85% of variance is attributable to differences between rats, 2% to the difference in runs, and 14% to the remaining measurement variability.
Since the two cross-sectional studies were performed in the same facility, with the same dose and source of D 3 -creatine, with the same rat sex and strain, and the same analytical methods, and given the relatively low variability of the IRMS enrichment determinations between runs, the data were viewed collectively to compare LBM and total creatine pool size. Figure 6 shows the correlation between LBM and creatine pool size for all 40 rats used in the two cross-sectional studies (r ϭ 0.9590; P Ͻ 0.001). Even after taking into account age and treatment effects, there is a strong relationship between the independent measure of LBM by QMR and total body creatine pool size by the D 3 -creatine dilution method (r ϭ 0.7640; P Ͻ 0.0001; data not shown). Power calculations based on the combined data (pooled SD estimate ϭ 157 mg) indicated that with a sample size of 10 rats per group the smallest mean difference in total creatine pool size detectable by the D 3 - Fig. 4 . Relationship between LBM determined by QMR and creatine (Cr) pool size determined by D3-creatine dilution in 22-wk-old rats treated the previous 2 wk with either vehicle (n ϭ 10; mean body weight 599 Ϯ 58 g) or dexamethasone (dex) (n ϭ 10, mean body weight 478 Ϯ 43 g), adjusted for treatment effect(r ϭ 0.7958, P Ͻ 0.0001). Comparison of urinary D3-creatinine and skeletal muscle D3-creatine enrichments in 22-wk-old rats treated the previous 2 wk with either vehicle or dexamethasone (n ϭ 10). TA, tibialis anterior; quads, quadriceps; gastroc, gastrocnemius; EDL, extensor digitorum longus. *Significantly higher than corresponding urine enrichment within same treatment group (Bonferroni adjusted P Ͻ 0.05). #Significantly lower than corresponding soleus enrichment within same treatment group (Bonferroni adjusted P Ͻ 0.05). creatine dilution method is 242 mg (corresponding to, for example, a 13% change in the creatine pool size of a 22-wk-old rat), using a two-sided hypothesis test at the 0.05 level and 90% power.
Relation of total body creatine pool size to skeletal muscle mass. Caster et al. (9) performed a dissection of every muscle, perhaps the most accurate assessment of total-skeletal muscle, and reported that a rat of similar age and size to those used in the present study were 45.5% skeletal muscle as percent of body weight. However painstaking the method may be, a clean dissection of every muscle very likely may not be possible. We did, however, dissect and weigh from every rat the four major muscles of the lower limb-soleus, EDL, gastrocnemius, and TA-that are relatively easy to completely and consistently remove. The sum of the weight of these muscles strongly correlated with LBM (r ϭ 0.9574, P Ͻ 0.0001; r age&treatment-adjusted ϭ 0.8079, P Ͻ 0.0001, data not shown) and with total-body creatine pool size (r ϭ 0.9202, P Ͻ 0.0001; r age&treatment-adjusted ϭ 0.6959, P Ͻ 0.0001), further supporting the relationship of total-body creatine pool size determined by the D 3 -creatine dilution method to skeletal muscle mass (Fig. 7) . Mean fat mass was also measured by QMR in all rats in this study, and it also increases with age and decreases with dexamethasone treatment. However, in contrast to the highly significant correlation between creatine pool size and LBM or muscle mass, no correlation was seen between fat mass and creatine pool size (P ϭ 0.2634, data not shown) after adjusting for age and treatment effects, lending further support to the relationship of creatine pool size to skeletal muscle.
Conversion of total body creatine pool size to skeletal muscle mass is complicated by the differential creatine content of specific muscles, particularly in the rat. Muscle such as rat soleus (mainly oxidative fibers) has 1.65-fold less creatine content than muscle such as rat EDL or white gastrocnemius (7, 16) . Therefore, accurate conversion of creatine pool size to muscle mass includes knowledge of the fiber type composition of the individual. We have assessed whether the creatine pool sizes we have calculated correspond to expected muscle mass composition in rats in the following manner. We have estimated the muscle mass composition based on the extreme assumptions of near 100% oxidative or 100% glycolytic fibers. We used the values or Brault and Terjung of 3.1 and 5.1 mg/g wet weight muscle for oxidative (soleus) or glycolytic (white gastrocnemius) in rats, and the enrichments given in Fig. 5 for soleus (0.052%) and EDL (0.030%) for 22-wk-old rats. Dividing these enrichments into the D 3 -creatine dose (0.475 mg) to determine total-body creatine pool size, and dividing creatine pool size by the muscle creatine content, this yields a muscle mass composition of 49 and 51% of body weight, respectively, for a hypothetical rat with nearly 100% oxidative or glycolytic fibers, respectively. Rats have greater than 75% glycolytic fibers (2, 3) , so an estimate of skeletal muscle composition based on a 75:25 ratio of glycolytic:oxidative fibers would be 51% of body weight. Furthermore, our growing rats gained LBM and creatine pool size at the rate of about 1.5% per day between 9 and 22 wk of age, and the creatine dilution estimates were made 3 days after D 3 -creatine administration and body weight determination, so one could subtract ϳ2-3% of muscle mass, for a final estimate of ϳ48% skeletal muscle mass by body weight.
DISCUSSION
We report here a new method for the determination of total-body skeletal muscle mass using the dilution an orally dosed D 3 -creatine in muscle and the measurement of urinary D 3 -creatinine in rats. The method was validated against independent measures of lean mass after muscle mass accrual during growth and muscle wasting due to the effects of dexamethasone. Unlike the use of 24-h creatinine excretion, the present method requires collection of a single urine sample during isotopic steady state of creatinine enrichment.
The method development required finding a dose of tracer D 3 -creatine that was sufficiently large to allow detection of enrichment by IRMS in urine samples, and small enough to not saturate muscle creatine uptake and spill into urine. This dose selection was made with the knowledge that the plasma creatine levels in the rat is close to the K m for rat skeletal muscle creatine transporter (7, 18) . The dose of 0.475 mg/rat resulted in minimal urinary spillage over the sizes and ages of rats examined in this study. In humans, creatine plasma levels are generally lower and this window for tracer dose selection may be larger.
Isotopic steady state in urinary creatinine enrichment was obtained by 48 h postdose and remained constant for up to 72 h. The stable nature of creatinine enrichment is expected and reflects a relatively slow turnover of intramuscular enrichment and the constant nature of production of creatinine (6) . Although we used a 72-h urine sample for determinations of creatine pool size in the present studies, precise timing after isotopic steady state is not critical due to the stable nature of urinary creatinine enrichment, and this flexibility will be advantageous both for future preclinical studies for and translation to the clinic.
A strong relationship was seen between LBM measured by either DEXA or QMR and total-body creatine pool size calculated from urinary enrichments by the D 3 -creatine dilution Fig. 7 . Correlation between lower limb muscle mass and total-body creatine pool size determined by D3-creatine dilution for all 40 rats used in the 2 cross-sectional studies (r ϭ 0.9202, P Ͻ 0.0001). Lower limb muscle mass for each rat is the sum of the individual weights of the left and right soleus, EDL, TA, and gastrocnemius muscle from that rat. method. The correlation was significant for each of the individual age or treatment groups of rats studied, and when the data were taken together, the correlation was striking (all rats, total creatine pool size vs. LBM by QMR, r ϭ 0.9590, P Ͻ 0.0001, n ϭ 40). The line for this comparison for all individual groups and the collective data did not go through zero and the y-intercept was always a positive number (Fig. 6 ). This likely reflects that LBM determined by QMR or DEXA includes more than just skeletal muscle and is influenced by body water and viscera, while total-body creatine pool size represents almost exclusively skeletal muscle (27) . In some instances, creatine pool size determinations revealed greater changes than those picked up by LBM determinations in the present crosssectional studies of known skeletal muscle mass change. For example, creatine pool size, but not LBM, was significantly increased between 17-and 22-wk-old rats. Also, the percentage increase in average creatine pool size comparing growing rat groups in the first study, and the percentage decrease in average creatine pool size comparing vehicle and dexamethasone treatments in the second study, were greater than the percentage change in average LBM. The slope of 0.2 indicates an increase of 0.2 g of LBM for every milligram increase in total-body creatine pool size. Power calculations indicate the present method can resolve a 242-mg change in total-body creatine pool size with groups of 10 rats in a cross-sectional study.
Together, these observations are consistent with the hypothesis that total-body creatine pool size is a more direct and accurate measure of skeletal muscle change than LBM by QMR or DEXA. The hypothesis is further supported by a strong relationship between muscle mass of easily dissected, representative hindlimb muscles and total-body creatine pool size (Fig. 7) . A critical element in validation of the method is calculation of total-body creatine pool size and skeletal muscle mass directly from D 3 -creatine muscle enrichment. Total-body creatine pool size based on muscle enrichment translated to a muscle composition of ϳ48% in a 22-wk-old male rat. This is slightly higher than the figure of 45.5% derived from a rigorous carcass dissection (9) , although this dissection was done with younger 16-wk-old rats, and muscle composition increases with growth (25) . A more likely explanation for greater muscle mass compared with gross dissection is the complete sampling of every muscle afforded by the D 3 -creatine dilution method relative to dissection, which cannot quantitatively account for every muscle in every anatomic compartment. Also, we have assumed that the entire 0.475-mg dose of D 3 -creatine tracer is available for dilution into the skeletal muscle creatine pool. If one accounts for Ͻ0.5% spillage of the tracer, and 98% of the total body creatine pool represented by skeletal muscle, our muscle mass determination would be reduced by ϳ2%. In summary, skeletal muscle mass calculated from muscle biopsy enrichments is in line with expected male rat muscle composition.
We found that muscle enrichments differed among muscle types, presumably due to fiber type distribution and the differential creatine uptake and creatine content of glycolytic and oxidative muscle fiber types (7) . More work would be needed to know whether this difference in enrichment may allow a gross prediction of fiber type composition in a muscle sample. Urinary enrichment of D 3 -creatinine trended to be lower than D 3 -creatine enrichment in muscle (although significantly different for only soleus and one example of TA), resulting in a total-body creatine pool size and muscle mass that is higher than that derived from muscle enrichments. For example, in the 22-wk-old cohort, using a figure of 4.6 mg average total creatine/g wet muscle weight and a muscle fiber composition of 75:25 glycolytic to oxidative muscle (7), urine enrichment would yield a relative muscle mass of 65% vs. the 48% derived from the muscle enrichments. Ideally, if one assumes that creatinine is derived only from creatine metabolism, urine creatinine comes only from skeletal muscle, creatine content in all muscles is equal, and creatine metabolism to creatinine is constant, urine enrichments and muscle enrichments would be identical. However, since muscle creatine content differs with fiber type, our hypothesis was that urine enrichment would be an integration of all muscle enrichment and urine creatinine enrichment should be intermediate to the muscle extremes. Thus the observation that urinary enrichments that are lower than in predominantly oxidative muscle is to be expected. The observation of urinary enrichments that are equal to or slightly lower than that of predominantly glycolytic muscles suggests that urinary enrichment is likely influenced by creatinine from nonskeletal muscle sources.
Potential sources of creatinine other than skeletal muscle include contribution of endogenous nonskeletal muscle creatine pools or contribution of dietary creatine and creatinine. Endogenous nonskeletal muscle pools would further dilute the tracer, and this possibility is less likely since creatine pool size and muscle mass determination based on muscle enrichment and the full tracer dose yielded the expected muscle mass in the present study. This would also be consistent with ϳ98% of endogenous creatine residing in skeletal muscle (11, 13) . Wang et al. (24) review that a small and inadequately characterized amount (Ͻ20% of total) of creatinine is produced in smooth muscles, brain, and other nonskeletal muscle organs. The upper side of this estimate is influenced by a report by Afting et al.
(1) of a subject with no skeletal muscle reporting 17% of urinary creatinine from nonskeletal muscle creatine sources, although study of urinary creatinine excretion in creatine-free diet-fed animals is consistent with the expected 2% from nonskeletal muscle sources (6) . Exogenous sources are thus the most likely source of the difference between urine and skeletal muscle enrichments.
The key practical question that remains is, how variable would this component of the analysis be across different physiological and disease conditions and clinical translation? We assume that for the present rat studies, any exogenous sources of creatine and creatinine would be relatively constant (animal husbandry identical in all studies). We have not yet tested this hypothesis, however, by varying creatine content of food, or disease model, aside from the steroid-induced wasting condition reported here.
The 24-h urinary creatinine excretion method for determination of muscle mass is based on many of the same premises of creatine biology as the D 3 -creatine dilution method. A major difference in the methods is that the D 3 -creatine dilution method does not rely on quantitative recovery of urinary creatinine; it depends only on the enrichment in a urine sample as a representative of skeletal muscle enrichment and, thus, is not affected by renal function. However, dietary creatine and creatinine of sufficient magnitude is likely to contribute to variability (estimated to contribute for Ϯ10 -30% of variability in the 24-h creatinine excretion method) (reviewed in Ref. 12) .
We assume for the D 3 -creatine dilution method that the in vivo conversion of creatine to creatinine occurs at a constant irreversible rate of ϳ2%/day (reviewed in Ref. 27 ). Chinn (10) indicated that it could be lower at 0.88% (10); however, Waterlow et al. (25) favored the higher rate. Waterlow et al. (25) also reported in preliminary studies that creatine metabolism may not be constant and can be accelerated in fasting and severe infection. In contrast, Reeds et al. (21) did not see a difference in the ϳ2% fractional turnover per day in malnourished and recovered pediatric subjects. Because this method measures only the enrichment of D 3 -creatine, however, the rate of conversion of creatine to creatinine should not, in principle, alter the enrichment of the creatinine that is produced and excreted into the urine. Moreover, D 3 -creatine enrichment is not affected by changes in glomerular filtration rate. To our knowledge, the existence or mechanism of a significant global change in creatine metabolism in different physiological disease states has not been rigorously investigated. There are reports of differential skeletal muscle creatine content in different disease states, including malnourished pediatric subjects (19, 21) and inflammatory conditions (reviewed in Ref. 4) , and Picou et al. (19) suggest such differences could limit the relation of daily creatine output to muscle mass in malnourished pediatric subjects. It is not clear whether such a differential creatine content reflects fundamental differences in creatine metabolism, fiber composition or consequence of muscle functional state. Future evaluation of the D 3 -creatine dilution method in different disease states could offer a new approach to these questions.
The present studies were cross-sectional in nature. Repeated measures for longitudinal determination of change in muscle mass must take into account muscle creatine enrichment prior to a subsequent dose of D 3 -creatine. We are currently conducting longitudinal trials in rodents to validate the method to measure gain or loss in creatine pool size and skeletal muscle mass, and determine whether paired comparisons within a longitudinal study will allow resolution of even smaller changes. This would enable both diagnostic and disease monitoring application in drug development and therapy. The D 3 -creatine dilution method holds considerable promise for translation to the clinic. It has advantages over the 24-h creatinine excretion method skeletal muscle mass, as it gives a direct measure of total-body creatine pool size, requires less effort from a subject/patient, and does not require exacting conditions of urine collection, for which compliance is often poor. It is a more direct measure than DEXA, which is not skeletal muscle-specific, or other expensive imaging methodologies (MRI, ultra-sound, CT) that are often under scheduling demand for urgent diagnostic procedures, and can involve exposure to radiation (CT). Imaging methods for determination of fat-free mass may also be prone to error related to shifts in body water content that often is associated with chronic diseases or therapeutic interventions.
As with the present preclinical study, clinical feasibility will depend upon selection of a suitable dose of D 3 -creatine, ideally low enough for minimal urinary spillage and high enough for urinary enrichment detection. The present laboratory analysis requires access to specialized IRMS instrumentation; exploration of analytical methods in more common use such as HPLC-MS/MS that could enable more routine application remains to be done, and further validation of the method could also drive innovation in dedicated instrumentation. While work could be done in the clinic to determine whether the spot urine could be taken earlier than 48 h, an advantage for clinical application is that enrichment should not decline by more than ϳ2% per day, and precise timing of spot urine collection within a couple of days should not be critical as long as the sample is obtained during isotopic steady state. In summary, the D 3 -creatine dilution method has the potential for routine office visit use, in the form of an oral capsule of D 3 -creatine, a single spot urine sample ϳ2 days later, and a laboratory analysis.
